An observational study in Parkinson Disease (PD), Periodontitis and Periodontal Diseases, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Saglik Bilimleri Universitesi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.
Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 6th largest by enrollment of the 73 observational ones that give a count, is one of 29 that started in 2026, is one of 73 observational ones, and was the 138th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:
Mustafa Kemal University · Sites in Turkey
Ages 35–75 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 40+
Acibadem University · Sites in Turkey
Ages 40–85
Kahramanmaras Sutcu Imam University · Sites in Turkey
Ages 40–75
Medipol University · Sites in Turkey
Ages 50–80
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 32 across the 99 interventional studies, 61 across the 73 observational. Of the 104 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 172 have an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
Saglik Bilimleri Universitesi has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
18 of the studies in Parkinson Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678983Izmir Bakircay UniversityWhole-Body Vibration in Parkinson Disease | 2026-12 |
| NCT06154356Karamanoğlu Mehmetbey UniversityAction Observation and Motor Imagery Therapy in Parkinson's Disease | 2026-12 |
| NCT07730073Atlas UniversityEfficacy of LSVT-LOUD Therapy on Voice, Speech, and Quality of Life in Parkinson's Disease | 2026-12 |
| NCT07010783Ankara UniversityRespiratory Functions in Parkinson's Disease | 2026-12-01 |
| NCT07641556Saglik Bilimleri UniversitesiThe Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease | 2026-12-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 172 studies in Parkinson Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the effects of Levodopa-Benserazide drug combination on periodontal status and salivary cytokine levels in patients with Parkinson's disease. The study includes four groups: Parkinson's patients with periodontitis, periodontally healthy Parkinson's patients, participants without Parkinson's with periodontitis, and periodontally healthy participants without Parkinson's. Clinical periodontal parameters (Plaque Index, Gingival Index, Bleeding on Probing, Pocket Depth, and Clinical Attachment Loss) will be recorded. Unstimulated saliva samples will be collected to analyze the levels of TNF-alpha, RANTES, IL-10, IL-13, Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Malondialdehyde (MDA).
Background and Rationale: Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra. Chronic inflammation and oxidative stress are considered significant factors in the progression of PD. Levodopa (L-DOPA), combined with Benserazide, remains the most effective pharmacological treatment for managing PD symptoms. Periodontitis is a chronic inflammatory disease that leads to the destruction of tooth-supporting tissues and is associated with elevated levels of local and systemic inflammatory cytokines such as TNF-alpha, IL-10, IL-13, and RANTES. Recent studies suggest a bidirectional relationship between systemic inflammation and neurodegenerative diseases. This study aims to evaluate the effects of the Levodopa-Benserazide drug combination on periodontal status and salivary inflammatory cytokine levels in patients with Parkinson's Disease.
Study Design and Setting: This cross-sectional, case-control study will be conducted in collaboration with the Department of Periodontology at the University of Health Sciences, Gulhane Faculty of Dentistry, and the Department of Neurology at Hacettepe University Faculty of Medicine.
Participants and Groups: The study will include a total of 136 participants divided into four groups (n=34 per group):
Parkinson's patients with periodontitis
Periodontally healthy Parkinson's patients
Systemically healthy participants with periodontitis (Control)
Systemically and periodontally healthy participants (Control)
Diagnosis of Parkinson's Disease will be confirmed based on the United Kingdom Parkinson's Disease Society Brain Bank Criteria.
Exclusion Criteria: Participants will be excluded if they have active smoking habits, diabetes mellitus, history of antibiotic or anti-inflammatory drug use in the last 3 months, periodontal treatment in the last month, use of probiotics or oral antiseptics in the last month, history of radiotherapy/chemotherapy in the last 6 months, presence of fewer than 16 natural teeth, use of removable partial or complete dentures, or inability to give informed consent due to dementia or other cognitive impairments.
Clinical Evaluations: All participants will undergo a comprehensive periodontal examination. Clinical parameters including Plaque Index (PI) (Silness-Löe), Gingival Index (GI) (Löe-Silness), Bleeding on Probing (BOP), Pocket Depth (PD), and Clinical Attachment Loss (CAL) will be recorded using a Williams periodontal probe. Measurements for PD, CAL, and BOP will be taken at six sites per tooth, while PI and GI will be recorded at four sites per tooth.
Biochemical Analysis: Unstimulated whole saliva samples will be collected from all participants between 09:00 and 10:00 AM to minimize circadian rhythm variations. Participants will be asked to refrain from eating, drinking, or oral hygiene procedures for at least one hour prior to collection. Samples will be stored at -80°C until analysis.
Inflammatory cytokines (TNF-alpha, RANTES, IL-10, IL-13) will be analyzed using Enzyme-Linked Immunosorbent Assay (ELISA).
Oxidative stress markers, including Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Malondialdehyde (MDA), will be measured using spectrophotometric methods.
Statistical Analysis: Data distribution will be assessed using the Kolmogorov-Smirnov test. Differences between groups will be analyzed using ANOVA (for normally distributed data) or appropriate non-parametric tests. Categorical variables will be compared using the Chi-square test. A p-value of \<0.05 will be considered statistically significant.
Participants will be recruited from the Department of Neurology at Hacettepe University Faculty of Medicine (Parkinson's patients) and the Department of Periodontology at the University of Health Sciences, Gulhane Faculty of Dentistry (Periodontitis patients and healthy controls).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with Parkinson's Disease who also have Periodontitis.
Patients diagnosed with Parkinson's Disease who are periodontally healthy.
Systemically healthy participants (non-Parkinson) who have Periodontitis.
Systemically and periodontally healthy participants.
Salivary Inflammatory Cytokine
TNF-alpha,
Time frame: Day 1
Salivary Inflammatory Cytokine
RANTES
Time frame: Day 1
Salivary Inflammatory Cytokine
IL-10
Time frame: Day 1
Salivary Inflammatory Cytokine
IL-13
Time frame: Day 1
Salivary Oxidative Stress Levels
Total Oxidant Status (TOS)
Time frame: Day 1
Salivary Oxidative Stress Levels
Total Antioxidant Status (TAS)
Time frame: Day 1
Salivary Oxidative Stress Levels
Malondialdehyde (MDA)
Time frame: Day 1
Clinical Periodontal Parameters
Assessment of Plaque Index (PI)
Time frame: Day 1
Clinical Periodontal Parameters
Bleeding on Probing (BOP)
Time frame: Day 1
Clinical Periodontal Parameters
Gingival Index (GI)
Time frame: Day 1
Clinical Periodontal Parameters
Pocket Depth (PD)
Time frame: Day 1
Clinical Periodontal Parameters
Clinical Attachment Loss (CAL)
Time frame: Day 1
Plan to share: Undecided
Ran from Feb 2026 to primary completion in Oct 2026, 8 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →